Science & academia

Good news for public health

Annual jab for HIV protection passes trial hurdle

By / / Good news links

An annual injection designed by California’s Gilead Sciences to guard against HIV has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. For the trial, 40 people without HIV were injected into the muscle with lenacapavir, with no major side effects or safety concerns. And after 56 weeks, the medicine was still detectable in their bodies. If future trials go well, it could become the longest-acting form of HIV prevention available.

Human eye up close

Stem cell therapy trial reverses “irreversible” damage to cornea

By / / Good news links

A new study conducted by scientists at Massachusetts Eye and Ear investigated a new treatment that removes stem cells from a patient’s uninjured eye, growing their population in the lab for a few weeks, then surgically transplanting them into the injured eye. The phase 1/2 trial recruited 14 patients to undergo the procedure. By the first checkup at three months, the corneas of seven (50%) of the participants had been completely restored. By the 12-month mark, that number had increased to 11 (79%) patients.

Illustration of the concept of nuclear fusion

France runs fusion reactor for record 22 minutes

By / / Good news links

Achieving the dream of commercial fusion power is the Holy Grail of engineering and has been for 80 years. With a single gram of hydrogen isotopes yielding the energy equivalent of 11 tonnes of coal, a practical fusion reactor would hold the promise of unlimited, clean energy for humanity until the end of time. France has upped the ante in the quest for fusion power by maintaining a plasma reaction for over 22 minutes – 25% longer than the previous record set by China in January 2025.

Two people holding hands

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good news links

The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off and adverse motor-function symptoms become amplified. In trial, Onapgo significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment.

Holding pills

U.S. FDA approves non-addictive alternative to opioids

By / / Good news links

The U.S. Food and Drug Administration has signed off on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. Crucially, suzetrigine creates no euphoria or high like opioids sometimes can, so doctors believe there’s no potential for it to create addiction or dependence in people who use it.

Illustration of the concept of nuclear fusion

China sets new fusion endurance record of over a thousand seconds

By / / Good news links

Fusion power is widely thought of as the holy grail of renewable, climate-friendly energy. Now, we are one step closer to realizing practical fusion power for the masses. The Experimental Advanced Superconducting Tokamak reactor in China’s Anhui Province has set a new record with a 1,066-second sustained fusion reaction. The new record builds on the previous record of 403 seconds set by EAST in 2023. The increase was made possible by a number of upgrades to the experimental system that have doubled the power output while keeping the reaction stable.

Woman with pink breast cancer ribbon

New therapy trial from Australian researchers nearly doubles breast cancer cure rates

By / / Good news links

A phase 3 clinical trial from Melbourne’s Peter MacCallum Cancer Center has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer. In the present phase 3 trial, 510 patients were randomized to receive chemotherapy with either intravenous nivolumab or placebo. In patients treated with nivolumab plus chemotherapy, rates were statistically significant, nearly double those who received placebo plus chemo: 24.5% versus 13.8%, respectively.

Depiction of intestines

“100% successful” cancer drug gets landmark U.S. FDA approval

By / / Good news links

Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the U.S. Food and Drug Administration granted it Breakthrough Therapy Designation status. The drug, a programmed death receptor-1-blocking antibody, completely eradicated rectal cancer tumors without the need for surgery, radiation treatment, or chemotherapy. “Everyone on the clinical trial is doing great,” Memorial Sloan Kettering Cancer Center gastrointestinal oncologist Andrea Cercek said. “So far, 42 people have completed treatment, and all of them have no evidence of disease. Side effects were quite mild and well tolerated.”

sidharth bhatia QstzxTWnXY unsplash scaled e

77% of universities have now pledged to divest from fossil fuels

By / / Good news links

115 U.K. universities have now pledged to exclude fossil fuel companies from their investment portfolios, following Birmingham City University, Glasgow School of Art, Royal Northern College of Music, and the University of Bradford all incorporating fossil fuel industry exclusions into their Ethical Investment Policies. The divested universities represent 77% of the U.K. Higher Education sector and more than $22 billion USD worth of endowments.

Molten iron ore

China develops new iron making method that boosts productivity by 3,600 times

By / / Good news links

The flash iron making method, as detailed by Professor Zhang Wenhai and his team in a paper published in the peer-reviewed journal Nonferrous Metals last month, can complete the iron making process in just three to six seconds, compared to the five to six hours required by traditional blast furnaces. According to Zhang and his colleagues, the new technology could improve energy use efficiency in China’s steel industry by over one-third. Additionally, by eliminating the need for coal entirely, it would help the steel industry achieve the goal of near-zero carbon dioxide emissions.